• Bryce J Bonin, Scott Beckman, Sultan Mahmud, Danielle Terrell, Stephen Garrett Whipple, Ryan Diaz, Nobel BhuiyanMohammad AlfradMADepartment of Internal Medicine at Louisiana State University Health Science Center, Shreveport, Louisiana., Deepak Kumbhare, Chiachien Jake Wang, Bharat Guthikonda, and Amey R Savardekar.
• Department of Neurosurgery at Louisiana State University Health Sciences Center, Shreveport, Louisiana.
• World Neurosurg. 2024 Oct 24.

PurposeTo analyze the current literature regarding use of SRS as primary treatment of VS to further evaluate efficacy and treatment-related neurologic deficits.MethodsOnline databases were queried to identify relevant publications from January 2001-December 2020. Full text, English articles for sporadic VS treated primarily with radiosurgery and documented hearing preservation data were reviewed. Papers that had a minimum follow-up period of less than 36 months, did not utilize radiosurgery for primary treatment, or included patients with Neurofibromatosis II were excluded.ResultsA total of 33 studies involving 4286 patients with an average follow-up of 62.5 months were included in the final analysis. All 33 studies included eligible hearing data; overall preservation of serviceable hearing was found to be 58.27%. 27 studies with 3822 eligible patients were analyzed for tumor control rates; overall, tumor control was reported in 92.98% of cases. 27 studies were analyzed for post-treatment facial nerve dysfunction which was reported in 1.53% of cases.ConclusionsSRS is a safe and effective primary treatment modality for sporadic vestibular schwannoma as evidenced by the present analysis. Radiosurgery is effective with regard to tumor control and hearing preservation while offering a low rate of post-treatment facial nerve dysfunction.Copyright © 2024. Published by Elsevier Inc.

5 keywords...

hide…